Thymoglobulin (Anti-Thymocyte Globulin (Rabbit)) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

Drug Interactions

• No drug interaction studies have been performed.
• Because Thymoglobulin is administered to patients receiving a standard immunosuppressive regimen, this may predispose patients to overimmunosuppression. Many transplant centers decrease maintenance immunosuppression therapy during the period of antibody therapy.
• Thymoglobulin can stimulate the production of antibodies which crossreact with rabbit immune globulins (See Pharmacokinetics and Immunogenicity ).

OVERDOSAGE

Thymoglobulin overdosage may result in leukopenia (including lymphopenia and neutropenia) or thrombocytopenia, which can be managed with dose reduction (See DOSAGE AND ADMINISTRATION ).

CONTRAINDICATIONS

Thymoglobulin is contraindicated in patients with history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections which contraindicate any additional immunosuppression.

REFERENCES

1. Bonnefoy-B©rard N, et al. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation (1991) 51 :669-673.
2. Bonnefoy-B©rard N, et al. Inhibition of CD25 (IL-2Ralpha) expression and Tcell proliferation by polyclonal anti-thymocyte globulins. Immunology (1992) 77 :61-67.
3. Bonnefoy-B©rard N, et al. Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood (1992) 79 :2164-2170.
4. Bonnefoy-B©rard N, Revillard J-P. Mechanisms of immunosuppression induced by antilymphocyte globulins and OKT3. J Heart Lung Transplant (1996) 15 :435-442.
5. Bourdage J, et al. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation (1995) 59 :1194-1200.
6. Broyer M, et al. Triple therapy including cyclosporine A versus conventional regimen–a randomized prospective study in pediatric kidney transplantation. Transplant Proc (1987) 19 :3582-3585.
7. Clark KR, et al. Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. Transpl Int (1993) 6 :18-21.
8. Gaber AO, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation (1998) 66 :29-37.
9. Guttmann RD, et al. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving Thymoglobuline and immunosuppression. Transplant Proc (1997) 29 (suppl 7A):24S-26S.
10. Ippoliti G, et al. Prophylactic use of rabbit ATG vs horse ALG in hearttransplanted patients under Sandimmun (CyA) therapy: clinical and immunological effects. Clin Transplantation (1989) 3 :204-208.

Manufactured for:                       By:               
Genzyme Corporation                         Genzyme Polyclonals, S.A.S.    
500 Kendall Street                               Marcy L’Etoile, France
Cambridge, MA 02142 USA              US License No. 1596    

©2007 Genzyme Corporation. All rights reserved.